Download PDF

1. Company Snapshot

1.a. Company Description

AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally.It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding.The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.


It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name.In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases.Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services.


AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

Show Full description

1.b. Last Insights on ACT

AlzChem Group AG's recent performance has been positively driven by robust financials, high insider ownership, and growth prospects. The company's strong alignment between management and shareholder interests, with significant insider ownership, signals confidence in its strategic direction. Additionally, AlzChem Group's financial health and potential for up to 70% earnings growth have drawn investor attention. Its stock may be undervalued, offering potential opportunities for growth as European markets experience a notable upswing.

1.c. Company Highlights

2. AlzChem's Q3 2025 Earnings: Strong Specialty Chemicals Drive Growth

AlzChem Group AG reported a robust Q3 2025, with sales increasing by 6.5% and 2% for the 9-month period, driven primarily by the Specialty Chemicals segment, which contributed 66% of sales. EBITDA grew by 12% to EUR 86 million, with an EBITDA margin of 20.3%. Earnings per share (EPS) came in at EUR 4.62, reflecting a strong operational performance. As CFO Andreas Losler noted, the improvement in EBITDA margin was due to stable depreciation and a positive financial result.

Publication Date: Nov -04

📋 Highlights
  • Specialty Chemicals Dominance:: The segment contributed 66% of total sales, with 9% sales growth and 16% EBITDA growth in Q3 2025.
  • EBITDA Expansion:: Group EBITDA surged by 12% to EUR 86 million, achieving a 20.3% margin driven by stable depreciation and positive financial results.
  • Balance Sheet Strength:: Total balance sheet increased by EUR 105 million, supported by EUR 56 million in customer grants for nitroguanidine expansion and EUR 85 million in contract liabilities.
  • Full-Year Guidance:: Sales projected to reach EUR 580 million and EBITDA to EUR 130 million by year-end, with no material U.S. tariff impact but potential risks from USD weakness.
  • Strategic Projects:: EUR 56 million nitroguanidine expansion and a 6-month calcium carbide furnace shutdown highlight CapEx and operational planning for future capacity growth.

Segment Performance

The Specialty Chemicals segment continued to drive growth, with sales increasing by 9% and EBITDA growing by 16%. The Basics & Intermediates segment reversed the downward trend in the first half of the year, although sales still decreased by 8%. The fertilizer segment showed encouraging development, indicating a positive outlook for the coming quarters.

Guidance and Outlook

AlzChem confirmed its guidance for the full year, expecting sales to grow to approximately EUR 580 million and EBITDA to reach EUR 130 million. The company remains cautious about the potential impact of U.S. tariff politics and the weakening U.S. dollar on sales and costs. Analysts estimate next year's revenue growth at 9.2%, indicating a continued positive trajectory.

Valuation Metrics

With a P/E Ratio of 26.78 and an EV/EBITDA of 14.65, AlzChem's valuation suggests that the market has priced in a certain level of growth. The ROE of 27.7% and ROIC of 17.9% indicate strong profitability. The Net Debt / EBITDA ratio of -0.16 suggests a healthy balance sheet with minimal debt.

Operational Updates

The company is making progress on its nitroguanidine expansion, having received EUR 56 million in customer grants. The maintenance shutdown of the calcium carbide furnace is expected to last approximately 6 months, and inventory levels are not expected to change significantly by the end of the year. The partnership with Ehrmann is also showing promise, with a successful market launch of creatine-based products.

3. NewsRoom

Card image cap

European Growth Companies With Insider Ownership Up To 28%

Nov -25

Source:

Card image cap

Is AlzChem Group AG (ETR:ACT) Trading At A 44% Discount?

Nov -24

Source:

Card image cap

We Think AlzChem Group's (ETR:ACT) Profit Is Only A Baseline For What They Can Achieve

Nov -08

Source:

Card image cap

European Market Gems 3 Stocks Estimated To Be Trading Below Intrinsic Value

Oct -31

Source:

Card image cap

3 European Growth Stocks With High Insider Ownership Expecting Up To 70% Earnings Growth

Oct -24

Source:

Card image cap

Are Robust Financials Driving The Recent Rally In AlzChem Group AG's (ETR:ACT) Stock?

Oct -15

Source:

Card image cap

European Value Stocks Offering Estimated Discount Opportunities

Sep -25

Source:

Card image cap

European Growth Companies With High Insider Ownership In September 2025

Sep -25

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.13%)

6. Segments

Specialty Chemicals

Expected Growth: 6%

AlzChem Group AG's Specialty Chemicals segment growth is driven by increasing demand for sustainable and eco-friendly products, expansion into emerging markets, and strategic partnerships. Additionally, the company's focus on research and development, as well as its ability to adapt to changing market trends, contribute to its growth.

Basics and Intermediates

Expected Growth: 4%

AlzChem Group AG's Basics and Intermediates segments demonstrate 4% growth driven by increasing demand for specialty chemicals, expanding customer base, and strategic capacity expansions. Additionally, the company's focus on sustainability and eco-friendly products contributes to growth, as customers prioritize environmentally responsible solutions.

Other and Holding

Expected Growth: 3%

AlzChem Group AG's Other and Holding segment growth is driven by strategic investments in sustainable projects, diversification of revenue streams, and optimization of operational costs. Additionally, the company's focus on innovation and R&D enables it to capitalize on emerging trends, further fueling growth.

7. Detailed Products

Creapure

High-quality creatine monohydrate for sports nutrition and pharmaceutical applications

Alzchem Fertilizers

Specialty fertilizers for agriculture, horticulture, and landscaping

Dytek

Amino acids and specialty chemicals for pharmaceutical, cosmetic, and industrial applications

Calcipan

Calcium carbonate for food, pharmaceutical, and technical applications

Alzchem Fine Chemicals

Custom manufacturing of fine chemicals for pharmaceutical, agrochemical, and specialty chemical industries

8. AlzChem Group AG's Porter Forces

Forces Ranking

Threat Of Substitutes

AlzChem Group AG operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the availability of alternative products.

Bargaining Power Of Customers

AlzChem Group AG has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

AlzChem Group AG relies on a few key suppliers for raw materials, which gives them some bargaining power. However, the company's long-term relationships with suppliers and its diversified supply chain mitigate this risk.

Threat Of New Entrants

The chemical industry has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to compete with AlzChem Group AG.

Intensity Of Rivalry

The chemical industry is highly competitive, with many established players competing for market share. AlzChem Group AG faces intense rivalry from other companies in the industry, which can lead to pricing pressure and reduced margins.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 26.78%
Debt Cost 5.79%
Equity Weight 73.22%
Equity Cost 9.16%
WACC 8.26%
Leverage 36.57%

11. Quality Control: AlzChem Group AG passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Uzin Utz

A-Score: 5.9/10

Value: 6.9

Growth: 5.0

Quality: 6.5

Yield: 4.4

Momentum: 9.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Sniezka

A-Score: 5.9/10

Value: 5.9

Growth: 3.9

Quality: 6.3

Yield: 6.9

Momentum: 7.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
AlzChem

A-Score: 5.4/10

Value: 1.8

Growth: 8.0

Quality: 7.2

Yield: 3.8

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Borregaard

A-Score: 5.1/10

Value: 3.1

Growth: 5.7

Quality: 6.5

Yield: 3.1

Momentum: 3.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Corbion

A-Score: 5.0/10

Value: 6.7

Growth: 7.4

Quality: 4.3

Yield: 4.4

Momentum: 1.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
EPC

A-Score: 4.6/10

Value: 4.4

Growth: 7.4

Quality: 3.2

Yield: 0.6

Momentum: 6.0

Volatility: 6.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

144.6$

Current Price

144.6$

Potential

-0.00%

Expected Cash-Flows